Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11939097 | 0.81 | KIF11 (0.44) | ALDH1A1CYP2A6MAPTTSHRLMNA | |
| SCHEMBL1715955 | 0.81 | ESR1 (0.42) | ALDH1A1MAPTHPGDTSHRMEN1 | |
| SCHEMBL25249405 | 0.81 | POLB (0.46) | ALDH1A1CYP2A6MAPTMEN1LMNA | |
| SCHEMBL11939279 | 0.81 | ALDH1A1 (0.38) | ALDH1A1MAPTHPGDMEN1LMNA | |
| SCHEMBL11939086 | 0.81 | PDE4A (0.33) | MEN1KMT2APDE4A | |
| SCHEMBL1341564 | 0.80 | SGMS2 (0.44) | ALDH1A1MAPTTSHRMEN1KMT2A | |
| SCHEMBL1716349 | 0.78 | KIF11 (0.46) | LMNADHODHTGM2CA1CA2 | |
| SCHEMBL193237 | 0.78 | MAPT (0.39) | ALDH1A1CYP2A6MAPTHPGDLMNA | |
| SCHEMBL24377332 | 0.78 | GAA (0.48) | ALDH1A1MAPTTDP1GAANPSR1 | |
| SCHEMBL17940976 | 0.76 | MMP3 (0.44) | ALDH1A1MAPTHPGDTSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894884-A | Trifunctional organic catalyst, and preparation method and application thereof | 浙江大学 | 2023-04-04 | — | — | CN | claimed |
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-30 | — | — | US | disclosed |
| CN-115894884-B | Trifunctional organic catalyst and preparation method and application thereof | 浙江大学 | 2024-07-05 | — | — | CN | disclosed |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| CN-116003328-A | Diaryl hydantoin compounds | 加利福尼亚大学董事会 | 2023-04-25 | — | — | CN | disclosed |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| CN-115894884-A | Trifunctional organic catalyst, and preparation method and application thereof | 浙江大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-110003114-B | Diarylhydantoin compounds | 加利福尼亚大学董事会 | 2023-01-17 | — | — | CN | disclosed |
| EP-3970721-A1 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| EP-1893196-B1 | DIARYLHYDANTOIN COMPOUND | UNIV CALIFORNIA (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011103202-A2 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011029392-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | TONG YOUZHI (CN) | 2011-03-17 | — | — | WO | disclosed |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-08 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1893196-A4 | DIARYLHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1893196-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006124118-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | ALDH1A1 911/4885CYP2A6 512/4885MAPT 2915/4885 |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | AR, BRDT, GNRHR | ALDH1A1 1572/4885CYP2A6 1209/4885MAPT 3598/4885 |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | ALDH1A1 1580/4885CYP2A6 2766/4885MAPT 3438/4885 |
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | ALDH1A1 911/4885CYP2A6 512/4885MAPT 2915/4885 |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | ALDH1A1 911/4885CYP2A6 512/4885MAPT 2915/4885 |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | ALDH1A1 911/4885CYP2A6 512/4885MAPT 2915/4885 |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | ALDH1A1 911/4885CYP2A6 512/4885MAPT 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.